Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis

Mark Topazian; Thomas E. Witzig; Thomas C. Smyrk; Jose S. Pulido; Michael J. Levy; Patrick S. Kamath; Suresh T. Chari

doi:10.1016/j.cgh.2007.12.020

Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis

Mark Topazian, Thomas E. Witzig, Thomas C. Smyrk, Jose S. Pulido, Michael J. Levy, Patrick S. Kamath, Suresh T. Chari

Research output: Contribution to journal › Article › peer-review

139 Scopus citations

Abstract

Background & Aims: Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy. Methods: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes. Results: The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved. Conclusions: Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.

Original language	English (US)
Pages (from-to)	364-366
Number of pages	3
Journal	Clinical Gastroenterology and Hepatology
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.cgh.2007.12.020
State	Published - Mar 2008

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/j.cgh.2007.12.020

Cite this

@article{7b4e03a1289c4350b470d5beecb1885c,

title = "Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis",

abstract = "Background & Aims: Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy. Methods: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes. Results: The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved. Conclusions: Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.",

author = "Mark Topazian and Witzig, {Thomas E.} and Smyrk, {Thomas C.} and Pulido, {Jose S.} and Levy, {Michael J.} and Kamath, {Patrick S.} and Chari, {Suresh T.}",

year = "2008",

month = mar,

doi = "10.1016/j.cgh.2007.12.020",

language = "English (US)",

volume = "6",

pages = "364--366",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis

AU - Topazian, Mark

AU - Witzig, Thomas E.

AU - Smyrk, Thomas C.

AU - Pulido, Jose S.

AU - Levy, Michael J.

AU - Kamath, Patrick S.

AU - Chari, Suresh T.

PY - 2008/3

Y1 - 2008/3

N2 - Background & Aims: Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy. Methods: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes. Results: The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved. Conclusions: Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.

AB - Background & Aims: Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy. Methods: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes. Results: The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved. Conclusions: Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.

UR - http://www.scopus.com/inward/record.url?scp=39849102835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39849102835&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2007.12.020

DO - 10.1016/j.cgh.2007.12.020

M3 - Article

C2 - 18328441

AN - SCOPUS:39849102835

SN - 1542-3565

VL - 6

SP - 364

EP - 366

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 3

ER -

Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4-Associated Cholangitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this